Management of autoimmune bullous diseases: Pharmacology and therapeutics - 24/08/11
Cincinnati, Ohio
Abstract |
Bullous diseases are associated with high morbidity and mortality. They result from autoimmune response to one or more components of the basement membrane or desmosomes. Management consists of treating the immunologic basis of the disease, treating the inflammatory process involved in lesion formation, and providing supportive care both locally and systemically. Therapeutic agents are chosen based on their known pharmacologic properties and evidence of effectiveness derived from observations and studies.
Learning objectives |
At the completion of this learning activity, participants should be able to understand the pharmacology of drugs used in the treatment of bullous diseases, the principles of therapy for various such diseases, and a practical approach to the management of these diseases.
Le texte complet de cet article est disponible en PDF.Abbreviations : BP, CLL, DIF, EBA, ECP, Ig, IVIg, MTX, PF, PV
Plan
Funding sources: None. Conflicts of interest: None identified. |
Vol 51 - N° 6
P. 859-877 - décembre 2004 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?